01—Abstract
Summary
Summary of the 10-Q filed August 4, 2026. Cited figures are marked; the original filing is the authoritative source.
DuPont de Nemours, Inc. reported second-quarter 2026 net sales of $1.82 billiona, up from $1.75 billion a year earlier, with the filing stating organic sales rose 4 percent.
Income from continuing operations before income taxes was $266 millionb versus $78 million in the prior-year quarter, and net income available for DuPont common stockholders was $143 million, or $1.05 per basic share, compared with $59 million in the year-earlier period. Results for the period include discontinued operations, which posted a loss of $44 million in the quarter, reflecting MOU-related activity and a $125 million North Carolina accrual, partly offset by gains tied to the Aramids Divestiture. The Aramids business was sold to Arclin on April 1, 2026, for pre-tax cash proceeds of approximately $1.2 billion, a $300 million note receivable and a roughly 16 percent equity interest valued at $325 million.
Cash and cash equivalents rose to $1.74 billionc at June 30, 2026, from $715 million at December 31, 2025, and the company reported $2.9 billion of working capital. Total debt was $3.125 billion, and the company repurchased about $275 million of stock in May under an accelerated share repurchase, with a further $250 million expected in the third quarter. The filing also highlights ongoing PFAS exposure.
The company's share of the New Jersey settlement is recorded at a net present value of $188 milliond, and the AFFF multidistrict litigation includes approximately 12,400 personal injury cases. The company stated it is unable to estimate losses above the amounts accrued, and the 2026 DuPont Restructuring Program anticipates charges of approximately $75 million through 2028.
02—Key points
Key Highlights
- Net sales of $1.82 billion in Q2 2026, up from $1.75 billion, with organic sales up 4 percent; six-month net sales of $3.5 billion.
- Income from continuing operations before income taxes of $266 million in Q2 2026 versus $78 million in Q2 2025; six-month figure of $447 million versus $175 million.
- Net loss from discontinued operations of $44 million in Q2 2026, driven by MOU activity and a $125 million North Carolina accrual, offset in part by an $82 million gain on the Aramids Divestiture.
- Aramids Divestiture closed April 1, 2026, with approximately $1.2 billion of pre-tax cash proceeds, a $300 million note receivable and an equity interest valued at $325 million.
- Cash and cash equivalents of $1.74 billion at June 30, 2026, versus $715 million at December 31, 2025; total debt of $3.125 billion.
- Share repurchases include a $275 million accelerated share repurchase completed in May 2026, with a further $250 million of repurchases expected in Q3 2026 under the $2B Authorization.
- PFAS exposure remains significant: the New Jersey settlement share is carried at $188 million net present value and about 12,400 personal injury cases are pending in the AFFF MDL.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 4, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $1.82B$1.75B | +4.0% |
| Cost of Revenue | $1.18B$1.14B | +3.2% |
| Gross Profit | $639.00M$606.00M | +5.4% |
| R&D Expenses | $42.00M$53.00M | −20.8% |
| SG&A Expenses | $269.00M$262.00M | +2.7% |
| Net Income | $143.00M$59.00M | +142.4% |
| EPS (Basic) | $1.05$0.42 | +150.0% |
| EPS (Diluted) | $1.05$0.42 | +150.0% |
| Shares Outstanding (Basic) | 135.90M139.60M | −2.7% |
| Shares Outstanding (Diluted) | 136.80M139.90M | −2.2% |
05—Questions
Frequently Asked Questions
How did DuPont's revenue and profitability change in the second quarter of 2026?
Net sales rose to $1.82 billion from $1.75 billion, with the filing citing 4 percent organic sales growth. Income from continuing operations before income taxes increased to $266 million from $78 million, and the effective tax rate on continuing operations was 28.2 percent compared with 69.2 percent a year earlier, which the filing attributes primarily to transaction-related items recognized in 2025.
What was the effect of the Aramids sale on the financial statements?
The Aramids Business is presented as discontinued operations. The company recognized an $82 million gain in the second quarter when the disposal group's carrying value was finalized, and it recorded a total loss on sale of $378 million. Following the closing, DuPont holds an approximately 16 percent equity interest in Arclin, which will be accounted for using the equity method with a three-month lag.
What is the status of PFAS-related liabilities?
The company has accrued liabilities under the MOU and related agreements, including $530 million in total liabilities accrued under the MOU as of June 30, 2026. The New Jersey settlement is payable over 25 years, with DuPont's share at a net present value of $188 million, and the filing states that the court is expected to enter its final order. The company says it cannot estimate a possible loss above amounts accrued and that costs qualifying as Qualified Spend are limited by the MOU terms.
How is DuPont returning cash to shareholders?
The company declared a third-quarter 2026 dividend of $0.60 per share, payable September 15, 2026. It completed a $275 million accelerated share repurchase in May 2026 and announced on August 4, 2026 that it expects to repurchase $250 million of common stock in the third quarter under its $2B Authorization. Approximately $1.2 billion remained available under that authorization as of the end of the quarter.
What changed in DuPont's balance sheet and liquidity position?
Cash and cash equivalents increased to $1.74 billion from $715 million at year-end 2025, and total debt was $3.125 billion. Net working capital rose to $2.86 billion from $1.73 billion, and the current ratio was 2.43:1. The company reported no commercial paper outstanding at June 30, 2026, and it has undrawn revolving credit facilities totaling $2.75 billion.
06—Continue